Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Korea-U.S. Free Trade Agreement Likely To Put Stranglehold On Local Korean Drug Makers

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korean pharmaceutical companies are bracing for a tough time ahead if the governments of South Korea and the U.S. ratify a long-awaited Free Trade Agreement hammered out last year after eight rounds of negotiations between the two countries

You may also be interested in...



Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities

SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said

Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities

SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said

U.S. And South Korean Presidents Say More Negotiation Needed To Ratify Free Trade Agreement But Pharma Provisions Seen Intact

SEOUL - Although South Korean President Lee Myung-bak and U.S. President Barack Obama last week hinted at the possibility of more talks or a partial revision of their bilateral Free Trade Agreement in the U.S. Congress, pharma provisions outlined in the FTA aren't likely to be a bone of contention

Related Content

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel